Article By:
ChinaBio® Today
Saturday, September 2, 2017 4:57 PM EDT
Berry Genomics, a Beijing diagnostics and sequencing company, completed its $648 million reverse merger that lists the company on the Shenzhen exchange. And China's iPharma signed a $120 million deal for immunotherapy candidate in-license rights.